Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide 2.4 mg vs 1.0 mg and placebo for weight loss in Japanese adults
jRCT2080223935Phase 3Completed
- Start
- Jun 2018
- Modality
- Recombinant Proteins and Enzymes, Peptides
01
Overview
Phase 3, randomised, double-blind trial of semaglutide in obesity, Overweight, type 2 diabetes mellitus (T2DM) and 1 more (3 arms). Primary endpoints: Percentage change in body weight and Proportion of weight responders (≥5%, ≥10%, ≥15%). Started Jun 2018; status: completed.
02
Drugs
03
Conditions
obesityOverweighttype 2 diabetes mellitus (T2DM)hypertension (HTN)
Beyond the preview
Go deeper on jRCT2080223935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223935.